Related Experiment Video
Updated: Aug 18, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
[New therapeutic strategies in bronchial asthma]
1Universitatea de Medicină şi Farmacie Gr.T. Popa Iaşi, Facultatea de Medicină, Clinica II Pediatrie.
Abstract:
Bronchial asthma becomes one of the most frequent respiratory diseases of the childhood. Progresses of the last decade did not interfere with long term prognosis of the disease. New therapeutic researches try to stop the chronic inflammatory respiratory mechanism: cytokines, leukotrienes, transcription factors, IgE. Some of the new drugs are still only experimental--cytokines antagonists, transcription factors inhibitors, adhesin antibodies, other close to clinical use--new corticosteroids, leukotrienes antagonists, anti IgE antibodies. The new therapeutics methods will be used among the classical drugs and will improve the quality of the patients' life.
Insights
Childhood bronchial asthma remains common, with new therapies targeting inflammation. These treatments, including cytokine antagonists and anti-IgE antibodies, aim to improve patient quality of life.
Area of Science:
- Pediatric respiratory medicine
- Immunology
- Pharmacology
Context:
- Bronchial asthma is a prevalent childhood respiratory illness with persistent long-term prognosis challenges.
- Current therapeutic strategies focus on the chronic inflammatory pathways involved in asthma.
Purpose:
- To review emerging therapeutic research targeting key inflammatory mechanisms in bronchial asthma.
- To discuss novel drug candidates, including experimental and near-clinical options, for asthma management.
Summary:
- Research is exploring new treatments for childhood asthma by targeting cytokines, leukotrienes, transcription factors, and immunoglobulin E (IgE).
- Novel therapeutic agents include cytokine antagonists, transcription factor inhibitors, adhesin antibodies, advanced corticosteroids, leukotriene antagonists, and anti-IgE antibodies.
Impact:
- These new therapeutic approaches, used alongside established treatments, are expected to enhance the quality of life for pediatric asthma patients.
- Advances in asthma pharmacotherapy offer improved management options for this chronic respiratory condition in children.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.